Published in Nature on April 26, 2017
The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study (PEACE) | NCT03004755
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer (Safe-De) | NCT05058183
Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer (2017) 1.07
Lung cancer: Tracing tumour evolution. Nat Rev Clin Oncol (2017) 0.75
Progress and prospects of early detection in lung cancer. Open Biol (2017) 0.75
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol (2017) 0.75
Lung Cancer: A Wily Genetic Opponent. Cell (2017) 0.75
Circulating tumor DNA for personalized lung cancer monitoring. BMC Med (2017) 0.75
Cancer genomics: Human metastases under scrutiny. Nature (2017) 0.75
Towards a comprehensive framework for cell-free DNA analysis: lessons from TRACERx. Ann Transl Med (2017) 0.75
Cell-Free DNA in Oncology: Gearing up for Clinic. Ann Lab Med (2018) 0.75
Circular RNAs: Biogenesis, Function and Role in Human Diseases. Front Mol Biosci (2017) 0.75
Liquid-biopsies success highlights power of combining basic and clinical research. Nature (2017) 0.75
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics (2013) 5.61
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res (2014) 3.50
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med (2015) 3.33
Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med (2017) 2.48
Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res (2000) 2.13
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer (2007) 1.68
Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle (2009) 1.40
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer (2008) 1.38
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol (2014) 1.34
Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol (2016) 1.32
FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med (2000) 1.26
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun (2015) 1.25
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol (2016) 1.07
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med (2016) 1.06
Clonality inference in multiple tumor samples using phylogeny. Bioinformatics (2015) 1.05
Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. J Nucl Med (2015) 0.89
Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res (2014) 0.82
An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET. EJNMMI Res (2016) 0.81
Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: A brief review. Oncol Lett (2011) 0.79